Gene therapy fpr T cell-mediated autoimmunity: Teaching the immune system how to restrain its own harmful activities by targeted DNA vaccines

Israel Medical Association Journal

Volumn 2, Issue SUPPL. JULY, 2000, Pages 63-68

  Karin, N ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Chemokines; DNA vaccines; Experimental autoimmune encephalomyelitis; T cell mediated autoimmunity; Tolerance

Indexed keywords

CHEMOKINE; DNA VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNITY; CONFERENCE PAPER; DISEASE RESISTANCE; DRUG TOLERANCE; ENCEPHALOMYELITIS; GENE THERAPY; GENE TRANSFER; IMMUNE SYSTEM; IMMUNOSTIMULATION; NONHUMAN; RAT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ALLERGIC ENCEPHALOMYELITIS; ANIMAL; ARTHRITIS; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; DISEASE MODEL; DISEASE PREDISPOSITION; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MULTIPLE SCLEROSIS; REVIEW; VACCINATION;

ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE THERAPY; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; MACROPHAGE INFLAMMATORY PROTEIN-1; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, DNA;

EID: 0034222654     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (76)

1. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals
2. Major T cell responses in multiple sclerosis
3. Escape from 'horror autotoxicus': Pathogenesis and treatment of autoimmune disease
4. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-a) by targeted DNA vaccine confers long lasting resistance to experimental autoimmune encephalomyelitis
5. Long lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines
6. Prevention of experimental autoimmune encephalomyelitis by MIP-1alpha and MCP-1 Naked DNA Vaccines
7. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis
8. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein
9. Vaccination against experimental autoimmune encephalomyelitis using a subencephalitogenic dose of autoimmune effector cells (1). Characteristics of vaccination
10. Vaccination against experimental autoimmune encephalomyelitis using a subencephalitogenic dose of autoimmune effector T cells. (2). Induction of a protective anti-idiotypic response
11. Regulatory circuits in autoimmunity: Recruitment of counter-regulatory CD8+ T cells by encephalitogenic CD4+ T line cells
12. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions
13. Role of cytokines in determining T-lymphocyte function
14. Functional diversity of helper T lymphocytes
15. IL-4 directs the development of Th2-like helper effectors
16. Cytokine transcriptional events during helper T cell subset differentiation
17. IL-12 acts directly on CD4+ T cells to enhance priming for IFN-g production and diminishes IL-4 inhibition of such priming
18. The presence of interleukin-4 during in vitro priming determines the cytokine-producing potential of CD4+ T cells from T cell receptor transgenic mice
19. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells
20. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
21. The role of IL-10 in the crossregulation of Th1 and Th2 responses
22. IL-4 and IL-13 production in differentiated T helper type 2 cells is not IL-4 dependent
23. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients
24. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
25. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease
26. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats
27. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
28. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12
29. In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice
30. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells
31. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype
32. T helper subsets in insulin dependent diabetes
33. Th1 and Th2 CD4+ T-Cells in the pathogenesis of organ-specific autoimmune diseases
34. TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease
35. Interleukin-4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetec mice
36. Interleukin-10 prevents experimental allergic encephalomyelitis in rats
37. Interleukin-12 and its role in the generation of Th1 cells
38. Prevention of experimental autoimmune encephalomyelitis by antibodies to interferon gamma inducing factor
39. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin
40. Selective and nonselective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis
41. Short peptide based tolerogens without antigenic activity reverse autoimmunity
42. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
43. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of IFN-g and TNF-a production
44. T cell determinants of myelin basic protein include a unique encephalitogenic I-E-restricted epitope for Lewis rats
45. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. I: T cell receptor peptide regulation of T cell clones expressing cross-reactive V beta genes
46. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
47. Shifts in the epitopes of myelin basic protein recognized by Lewis rat T cells before, during, and after the induction of experimental autoimmune encephalomyelitis
48. Resistance to experimental autoimmune encephalomyelitis induced by neonatal tolerization to myelin basic protein: Clonal elimination vs. regulation of autoaggressive lymphocytes
49. Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein
50. Definition of encephalitogenic and immunodominant epitopes of guinea pig myelin basic protein (Gp-BP) in Lewis rats tolerized neonatally with Gp-BP or Gp-BP peptides
51. Induction of tolerance to one determinant on a synthetic peptide does not affect the response to a second linked determinant. Implications for the mechanism of neonatal tolerance induction
52. Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation
53. Clonal deletion versus clonal anergy: The role of the thymus in inducing self tolerance
54. T cell tolerance by clonal elimination in the thymus
55. Expansion of neonatal tolerance to self in adult life. II: Tolerance preferentially spreads in an intramolecular manner
56. Expansion of neonatal tolerance to self in adult life. I: The role of a bacterial adjuvant in tolerance spread
57. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
58. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen
59. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes
60. Systemic immunological effects of cytokine genes injected into skeletal muscle
61. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization
62. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
63. Vaccination against tuberculosis by DNA injection
64. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity
65. Tolerance, danger, and the extended family
66. The immune system evolved to discriminate infectious nonself from noninfectious self
67. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire
68. Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection
69. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage
70. Regulatory T-cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
71. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain
72. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
73. Antigen-induced programmed T cell death as a new approach to immune therapy
74. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomylitis
75. From antilymphocyte serum to therapeutic monoclonal antibodies: First experiences with a chimeric CD4 antibody in the treatment of autoimmune disease
76. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs